AzTrials
AzTrials

Decompensated CirrhosisH@HNCT06396897

Hospital @ Home Model of Care for Cirrhosis

A study testing Indiana University Health Hospital at Home Program in people with Decompensated Cirrhosis, run by Indiana University at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectations, perceived barriers, and drivers. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Decompensated Cirrhosis
What is being tested?
Indiana University Health Hospital at Home Program
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteUnited States
Study dates
10 May 2024to 31 Dec 2028
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Enrolled into IUH's H@H program
  • At least 18 years of age
  • Chronic liver disease/cirrhosis based on characteristic clinical, laboratory, and imaging findings
  • English speaking
  • Able to provide consent
  • Caregiver able to be present during the acute phase of care (first 48 hours post-hospital discharge)
  • Able to perform activities of daily living independently
  • Lives within IU Health Home service area

Who cannot join

  • Unable to complete study questionnaires due to neurocognitive disease, legal blindness or hearing loss
  • Transplant of organ other than liver
  • Pregnant
  • Incarcerated
  • New hemodialysis
  • Blood pressure < 90/60, Pulse > 120, O2 > 6L or >2L above baseline
Show all 9Show fewer
  • HIV+/CD4 count < 200
  • Receiving hospice services
  • Concurrent enrollment in a related research study

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Regia Weber contact

317-278-3584

reginaw@iu.edu

Archita Desai, MD contact

(317) 278-1664

desaiar@iu.edu

United States1 site, 1 recruiting
  • IU School of Medicine

    Indianapolis, Indiana, 46202

    Miranda Stovall, (317) 278-2401, mirstova@iu.edu

    Recruiting

Other trials in United States

About this study

Official title: The Hospital @ Home Model of Care: A Novel Healthcare Solution for the Management of Decompensated Cirrhosis

The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectations, perceived barriers, and drivers. H@H is an emerging model of home-based care, designed to extend traditional, inpatient hospital care which may address these needs. Through H@H, acute medical care services as well as ancillary care such as rehabilitation therapy can be delivered in the home. The study is divided into three phases: Phase 1 occurs while the participant is an inpatient. Phase 2 is when the actual H@H program takes place as part of the participant's clinical care. The study team will not be involved in the Phase 2 - H@H program as it will be conducted by the clinical staff. Phase 3, at which point the participant enters a rehabilitation phase to transition the patient to self-management, involves a research jam session with the participant and caregiver to assess the value of the program.

Read the detailed description

Hospital at Home (H@H) as an emerging model of care is designed as an extension for traditional inpatient hospital care. Patients experiencing certain medical conditions normally requiring admission to an inpatient hospital can instead consent to receive acute care treatment in their homes. Prior studies have shown success of this model through demonstration of clinical and economic efficacy and feasibility, as well as greater satisfaction with care for patients, their family members and their providers. Since November 2020, Centers for Medicare and Medicaid Services has provided a waiver for H@H services. Similarly in 2020, Indiana University Health (IUH) introduced the Hospital at Home (H@H) Program for its beneficiaries to increase hospital capacity during the Public Health Emergency. Through this program, primary medical management services as well as ancillary services such as Occupational Therapy, Physical Therapy, and diagnostic testing can be delivered in the home. This model has been successful used at IUH to management patients with moderate COVID-19 infection, common infectious diseases, and decompensated heart failure.

In the realm of liver disease, acute decompensations of chronic liver disease often require hospitalizations for acute management. In certain clinical scenarios, while the initial 24-48 hour period may require the intensive management offered in an acute care hospital, the remaining hospital days represent less acute and/or intense needs such as continued administration of IV medications, monitoring for safe transition to oral medications and/or daily lab monitoring for period of time. We hypothesize that services through the IUH H@H program can offer equally safe and effective for these clinical scenarios while improving patient satisfaction, reducing care-giver burden, being cost-saving and improving access to acute care hospital services to other patients. We also hypothesize that completing the acute care management in the home setting will lead to more effective transition to chronic management as measured by subsequent 30-day readmissions and 30-day emergency room visits leading to reduced overall cost of health care. As a next step in expansion, the IUH H@H team is partnering with the PI and IUH Hepatology team to manage select patients with chronic liver disease (CLD). The overall goal of this proposal is to assess whether IUH's H@H program represents a novel care delivery model in cirrhosis that is safe, improves patient and caregiver experience as well as reduces HCU in the high-risk, CLD population.

Being tested
Indiana University Health Hospital at Home Program

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Indiana University Health Hospital at Home ProgramOther

    Structure of Care in IUH H@H Program: The IUH H@H program allows patients to be cared for at home using home remote monitoring devices, travel laboratory services and both in-person and virtual rounding by the health care team. The team includes registered nurses (RN), advanced practice provider (APP, nurse practitioner and physician assistants) and hospitalist physician. Care at home is divided into 4 consecutive phases after initial hospitalization: (1) evaluation/planning, (2) acute, (3) recovery, and (4) rehabilitation. All patients are sent home with a RPM tablet used to obtain vital signs, send messages between patient and RN, \& perform video visits. The device is Bluetooth enabled and does not require WiFi or a phone line. All data obtained is automatically pulled into the electronic medical record. The RN uses a device which enables remote physical exams, i.e., obtain heart, lung and bowel sounds, pictures (wounds, lines, etc.) for review by APP/MD.

Study groups in NCT06396897
Study groupRoleWhat they receive
Decompensated CirrhoticsOtherPhase 1: * two questionnaires to assess patient reported outcomes * an open-ended patient interview using a variety of patient-engagement methods to assess program expectations Phase 2: • completion of the Hospital at Home (H@H) program as part of clinical care. In brief, the Hospital at Home program (H@H) is an innovative care delivery method that aims to provide hospital-level care at home and facilitate the transition care from the hospital to the home. Phase 3: * researchers engage virtually to discuss actual experience, outcomes, and challenges. These will be semi-structured interviews about their perspectives on the program, including desired outcomes and expectations and perceived barriers and drivers and will last about two hours. * complete four questionnaires relating to quality of life.
Receives: Other: Indiana University Health Hospital at Home Program

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants enrolled into program

    Measured: Phase 1 Baseline

  2. Reason for enrollment failure

    Measured: Phase 1 Baseline

Secondary outcomes (11)
  1. Number of participants with follow-up consultations during Phase 2

    Measured: During H@H program and up to and including 90 days after program completion

  2. Number of participants with services utilized in the home during Phase 2

    Measured: During H@H program and up to and including 90 days after program completion

  3. Number of participants with ED visits

    ED visits, including repeat visits, will be tracked

    Measured: During H@H program and up to and including 90 days after program completion

  4. Number of participants with rehospitalization

    Measured: During H@H program and up to and including 90 days after program completion

  5. Number of participants with a liver transplant

    Measured: 30 and 90 days after H@H program completion

  6. Number of participants with hospice enrollment

    Measured: 30 and 90 days after H@H program completion

  7. Rate of Mortality

    Measured: up to 90 days after H@H program completion

  8. PSQ 18

    Patient Satisfaction Questionnaire

    Measured: at 2 weeks after H@H program completion

  9. Telemedicine Questionnaire

    Measured: at 2 weeks after H@H program completion

  10. ZBI-12

    Zarit Burden Interview Questionnaire

    Measured: at 2 weeks after H@H program completion

  11. Promis 29+2

    change in health related quality of life

    Measured: up to 90 days after H@H program completion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 May 2024
  2. Study start10 May 2024
  3. Primary completion30 Sep 2028 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Model description
We will perform a pilot study to establish the feasibility of enrollment, data collection, and outcome assessment for a future efficacy trial. Patients meeting pre-defined criteria will be offered care through H@H program as part of clinical care. The research team will partner with the clinical team to co-enroll into the study. Before starting H@H, patients wills be asked to participate in an interview and report HRQOL. During H@H care, participants will be followed for return to ED or hospital. After discharge from H@H, participants will complete patient satisfaction surveys within 2 weeks of discharge and be followed for 90-days for HCU and HRQOL. Caregivers will also be enrolled and surveyed on their experience. Furthermore, all participants and caregivers will be approached to complete an interview component to identify new opportunities and co-design a more refined H@H program, which we will call H@H 2.0.
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06396897
Sponsor's protocol ID
21905
Acronym
H@H
Status last verified
Sep 2026
First submitted
30 Apr 2024
Last updated
22 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in